20-F: Takeda Pharmaceutical Releases 20-F Filing for Fiscal Year Ended March 31, 2024

Takeda Pharmaceutical Company Limited releases its 20-F filing, detailing its business, financial condition, and operating results for the fiscal year ended March 31, 2024.

Summary

• Takeda Pharmaceutical Company Limited has released its 20-F filing for the fiscal year ended March 31, 2024.
• The filing details the company's business operations, financial condition, and results of operations.
• Takeda focuses on five key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies Immunology, Oncology and Neuroscience.
• The company's R&D efforts are concentrated in Gastrointestinal and Inflammation, Neuroscience, and Oncology.
• Takeda is committed to achieving net-zero greenhouse gas emissions from its operations by 2035 and across its value chain by 2040.
• The company's consolidated bonds and loans totaled JPY 4,843.8 billion as of March 31, 2024.
• Takeda expects to record JPY 140.0 billion of restructuring expenses in the fiscal year ending March 31, 2025, due to a multi-year efficiency program.
• The company's revenue from emerging markets was JPY 649.8 billion for the fiscal year ended March 31, 2024.
• Takeda is involved in ongoing litigation, including product liability, intellectual property, and commercial disputes.
• The company is subject to evolving tax laws and regulations, which may affect its tax liabilities.
• Takeda is subject to laws and regulations globally regarding privacy, data protection, and data security.
• The company is exposed to both physical and transition risks associated with climate change.
• Takeda is increasingly dependent on information technology systems, which face the risk of cyberattacks.
• The company's results of operations and financial condition may be affected by foreign currency exchange rate fluctuations.

Positives

• Takeda is committed to achieving net-zero greenhouse gas emissions from its operations by 2035 and across its value chain by 2040.
• The company is focused on translating science into highly innovative, life-transforming medicines.
• Takeda is investing in new capabilities and next-generation platforms internally and through a network of partnerships.
• The company is embracing data and digital technologies to improve the quality of innovation and accelerate execution.

Negatives

• Takeda expects to record JPY 140.0 billion of restructuring expenses in the fiscal year ending March 31, 2025, due to a multi-year efficiency program.
• The company is involved in ongoing litigation, including product liability, intellectual property, and commercial disputes.
• The company is subject to evolving tax laws and regulations, which may affect its tax liabilities.
• Takeda is subject to laws and regulations globally regarding privacy, data protection, and data security.
• The company is exposed to both physical and transition risks associated with climate change.
• Takeda is increasingly dependent on information technology systems, which face the risk of cyberattacks.
• The company's results of operations and financial condition may be affected by foreign currency exchange rate fluctuations.

Risks

• Research and development of pharmaceutical products are expensive and subject to significant uncertainties.
• Failure to comply with government regulations over product development, regulatory approvals, and reimbursement requirements.
• Failure to comply with laws and regulations governing the sales and marketing of products.
• Government policies and other pressures to reduce medical costs.
• Expiration or loss of patent or regulatory data or marketing protection.
• Difficulty maintaining the competitiveness of products.
• Inability to adequately expand product portfolio through third-party alliance arrangements.
• Use of third parties for the performance of certain key business functions.
• Dependence on third parties for the inputs for products.
• Manufacture of products is technically complex and highly regulated.
• Illegal distribution and sale by third parties of counterfeit versions of products.
• Substantial debt may limit ability to execute business strategy.
• Pursuit of acquisitions may not realize anticipated benefits and synergies.
• Restructuring initiatives may not provide expected benefits on the expected timeline.
• Significant operations across the world, including emerging markets, expose to additional risks.
• Difficulty implementing and resourcing corporate sustainability-related measures.
• Digital transformation initiatives may be unsuccessful.
• Increasing dependence on information technology systems.
• Inability to attract and retain key management and other personnel.
• Involvement in litigation relating to operations on an ongoing basis.
• Products may have unanticipated adverse effects or possible adverse effects.
• Subject to the risk of intellectual property infringement claims.
• Subject to evolving and complex tax and related risks.
• Changes in data privacy and protection laws and regulations.
• May incur claims relating to use, manufacture, handling, storage or disposal of hazardous materials.
• Results of operations and financial condition may be adversely affected by foreign currency exchange rate fluctuations.
• Business may be adversely affected by climate change, extreme weather events, earthquakes, civil or political unrest, terrorism or other catastrophic events.
• Social media platforms and new technologies present risks and challenges for reputation and business.
• Sales to wholesalers are concentrated, which exposes to credit risks and pricing pressures.
• May have to recognize additional charges on statements of profit or loss due to impairment of goodwill, other intangible assets and equity method investments.
• A holder of ADSs has fewer rights than a holder of common stock.
• Rights of shareholders under Japanese law may be more limited than under the laws of other jurisdictions.
• Because of daily price range limitations under Japanese stock exchange rules, a holder of ADSs who has surrendered his or her ADSs in favor of shares of common stock may not be able to sell his/her shares of common stock at a particular price on any particular trading day, or at all.
• U.S. investors may have difficulty in serving process or enforcing a judgment against us or our directors or executive officers.
• Investors holding less than a full unit of shares will have limited rights as shareholders.
• Dividend payments and the amount you may realize upon a sale of our ADSs will be affected by fluctuations in the exchange rate between the U.S. dollar and the Japanese yen.
• Our shareholders of record on a given record date may not receive the dividend they anticipate.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.

Key Dates

Keywords

Takeda Pharmaceutical, 20-F Filing, Financial Results, Pharmaceutical, Gastroenterology, Rare Diseases, Oncology, Neuroscience, Plasma-Derived Therapies, R&D, Financials, Healthcare